Tiziana Life Sciences Ltd (NASDAQ:TLSA) Short Interest Update

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 680,800 shares, an increase of 300.2% from the December 31st total of 170,100 shares. Currently, 1.0% of the shares of the stock are short sold. Based on an average daily volume of 348,300 shares, the short-interest ratio is presently 2.0 days.

Tiziana Life Sciences Stock Down 2.5 %

Shares of TLSA stock traded down $0.02 on Wednesday, hitting $0.69. 222,115 shares of the stock traded hands, compared to its average volume of 1,297,624. The firm has a 50 day simple moving average of $0.84 and a two-hundred day simple moving average of $0.94. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC increased its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 34.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,187 shares of the company’s stock after purchasing an additional 23,800 shares during the period. Zhang Financial LLC owned 0.09% of Tiziana Life Sciences worth $65,000 as of its most recent SEC filing.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.